# Tomer Kariv

> Tomer Kariv is a Series C investor at Pontifax (Herzliya) backing Therapeutics and Biotechnology. See 7 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Pontifax](https://shizune.co/investors/profile/pontifax)
- Location: Herzliya, Israel
- Total investments: 7
- Last investment: Feb 2025
- Lead investor: 14%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/pub/tomer-kariv/0/397/158

Tomer Kariv is a Series C investor at Pontifax in Herzliya focused on Therapeutics and Biotechnology. Tomer Kariv is based out of Herzliya,Tel Aviv, and is the the Co-Founder and Chief Executive Officer of Pontifax. Tomer previously served as the Board of Director at Keros Therapeutics. Tomer Kariv attended Harvard University.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Therapeutics | 3 | 43% |
| Biotechnology | 3 | 43% |
| Medical | 2 | 29% |
| Health Care | 2 | 29% |
| Biopharma | 1 | 14% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 2 | 29% |
| Series B | 1 | 14% |
| Funding Round | 1 | 14% |
| Post-IPO Equity | 1 | 14% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 3 | 43% |
| Israel | 1 | 14% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Abcuro | Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both autoimmunity and cancer. They leverage the systematic target validation and clinical insights gained by its founders to identify new targets. Their intensive use of bioinformatics to interrogate the transcriptome of human disease together with ex-vivovalidation in diseased tissue has uncovered new approaches to target key compartments of the immune system.The company was incorporated in 2015 and is based in Newton, Massachusetts. | $200M | Series C | Feb 12, 2025 |  |
| Abcuro | Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both autoimmunity and cancer. They leverage the systematic target validation and clinical insights gained by its founders to identify new targets. Their intensive use of bioinformatics to interrogate the transcriptome of human disease together with ex-vivovalidation in diseased tissue has uncovered new approaches to target key compartments of the immune system.The company was incorporated in 2015 and is based in Newton, Massachusetts. | $155M | Series B | Aug 17, 2023 |  |
| Arno Therapeutics | Arno Therapeutics is a biopharmaceutical company focused on creating value through the development of innovative products for the treatment of cancer patients. | $8M | Post-IPO Equity | Aug 16, 2016 |  |
| Arno Therapeutics | Arno Therapeutics is a biopharmaceutical company focused on creating value through the development of innovative products for the treatment of cancer patients. | $7.4M | Post-IPO Equity | Jan 13, 2016 |  |
| Arno Therapeutics | Arno Therapeutics is a biopharmaceutical company focused on creating value through the development of innovative products for the treatment of cancer patients. | $31M | Post-IPO Equity | Oct 30, 2013 |  |
| Otic Pharma | Otic Pharma is a clinical-stage pharmaceutical company focusing on the development and commercialization of products for disorders of the ear, nose, and throat (ENT). The company has two platform technologies, each of which has the potential to be developed for multiple ENT indications. The company is currently developing anasally-administered, combination drug product (OP-02) intended to address the underlying cause of otitis media and Eustachian tube dysfunction (OM/ETD), a condition that affects more than 700 million people around the world every year. Otitis media is one of the most common disease seen in pediatric practice and the most frequent reason children consume antibiotics or undergo surgery. The company also has a foam-based drug delivery technology platform (OP-01) that can be used to deliver drugs into the ear, nose, and sinus cavities. The company is currently developing OP-01 as an improved treatment option for acute otitis externa (“swimmers ear”). For more information on the company, please visit www.oticpharma.com |  | Series C |  |  |
| Applied Immune Technologies | Applied Immune Technologies Ltd. engages in development of therapeutic molecules for cancer, viral, and autoimmune diseases. The company develops T-Cell Receptor-Like (TCRL) antibodies that are targeted to intracellular-derived peptides for various therapeutic and diagnostic applications. Its TCRL antibodies also have diagnostic applications inpathology; and vaccine design, validation, and monitoring, as well as in the analysis of antigen presentation in disease. The company was formerly known as BioMimic Pharma. The company was founded in 2006 and is based in Haifa, Israel. | $4M |  |  |  |

7 of 7 investments shown.

## Co-investors
- [Bain Capital Life Sciences](https://shizune.co/investors/profile/bain-capital-life-sciences) — VC Fund, 2 deals together
- [Mass General Brigham Ventures](https://shizune.co/investors/profile/mass-general-brigham-ventures) — VC Fund, 2 deals together
- [New Leaf Ventures](https://shizune.co/investors/profile/new-leaf-ventures) — VC Fund, 2 deals together
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 2 deals together
- [Redmile Group](https://shizune.co/investors/profile/redmile-group) — VC Fund, 2 deals together
- [Samsara BioCapital](https://shizune.co/investors/profile/samsara-biocapital) — VC Fund, 2 deals together

## About Pontifax

VC Fund · Herzliya, Israel

Pontifax is a healthcare-dedicated venture capital firm.The fund focuses on innovative bio-pharma opportunities.

4 contacts available at Pontifax.

| Name | Title | Profile |
| --- | --- | --- |
| Ohad Hammer | Partner | https://shizune.co/investors/profile/ohad-hammer |
| Ran Nussbaum | Managing Partner and Co-Founder | https://shizune.co/investors/profile/ran-nussbaum |
| Tomer Kariv | Co-Founder and Chief Executive Officer | https://shizune.co/investors/profile/tomer-kariv |
| Momi Karako | Partner | https://shizune.co/investors/profile/momi-karako |

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Tomer Kariv invest in?

Tomer Kariv invests primarily in Therapeutics, Biotechnology and Medical startups, most often at Series C and Series B stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Tomer Kariv last invest?

The most recent investment recorded for Tomer Kariv closed in Feb 2025. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co